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INTRODUCTION
Gene-environment interaction is behind the pathobiology of 
most widespread human diseases such as obesity and associ-
ated cardiometabolic diseases (atherosclerosis, hypertension, 
type 2 diabetes and metabolic syndrome). These are viewed as 
lifestyle-related disorders, and nutrition is among the environ-
mental factors with the highest impact on human metabolic and 
vascular health. Whilst susceptibility to become Homo obesus 
(man the obese) is determined largely by (“thrifty”) genes, the 
current obesity epidemic is significantly influenced by adverse
lifestyle factors. Given our genetic background it is essentially 
infeasible for humans to self-regulate food intake under current 
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obesigenic and atherogenic environment, especially in our 
country Bulgaria, an epicenter of global healthquake induced 
by stroke and myocardial infarction.
Here we Dance Round (i) nutrigenomics in disease preven-
tion, particularly cardiometabolic diseases, and (ii) adiponu-
trigenomics of life expectancy, focusing on caloric restriction 
and its chemical mimetics, such as resveratrol. 
THE SCIENCE OF NUTRIGENOMICS 
Nutrigenomics (nutritional genomics) can be viewed as a 
nexus between health, molecular nutrition, and genes. Nu-
trigenomics covers a wide range of technologies concerned 
with elucidating how the genetic program operating in cells 
and tissues is potentially influenced by diet. There are three 
possible definitions for nutrigenomics: (i) “ … the application 
of high throughput genomics tools in nutrition research” (1), 
(ii) [nutrigenomics] “… seeks to examine ‘dietary signatures’ 
in cells, tissues and organisms and to understand how nutri-
tion influences homeostasis” (1), and (iii) “… the interface 
between the nutritional environment and cellular/genetic 
processes” (2).
All of these draw certain parallels with other “-omics” 
sciences, particularly pharmacogenomics, but the comparison 
cannot be pushed too far; nutrigenomics faces complications 
that the other areas do not face, notably the length and the 
complexity of exposures. Nutrigenomics and other “-omics” 
sciences and technologies, such as transcriptomics, proteom-
ics, metabolomics, and epigenomics, have added more com-
plex functional analysis to the basic sequence information 
provided by the Human Genome Project (3). 
Transcriptomics, for example, which uses microarrays, 
is a very valuable way of beginning to understand how nu-
tritional exposure influences gene expression on a genomic
scale (4). It is possible to group genes of interest for particular 
metabolic processes and capture information from all of these 
at once to see how the cell is functioning at any given time 
or under certain conditions. Such techniques are aided by the 
commercial development of chips orientated around particular 
metabolic or functional systems.
Proteomics uses protein separation usually on 2-D gels 
followed by quantification and identification often using mass
spectrometric techniques to investigate differential protein 
expression again under different conditions or with different 
underlying pathology. The presence or absence of certain 
key proteins can give information about the early stages of 
disease (5).
Metabolomics (or metabonomics) examines global pat-
terns of metabolites present in the cell or in body fluids in
response to specific dietary exposures. This requires powerful
statistical tools (chemometric analysis) to investigate differ-
ences in the NMR spectra or analytes detected by HPLC or 
other separation techniques (6).
Epigenomics. Epigenetics is the study of modifications to
the genome which are copied from one cell generation to the 
next but which do not involve changes to the primary sequence. 
These changes, mediated through modification of chromatin
proteins such as histones and through the methylation of DNA, 
contribute to the regulation of transcription and provide a way 
for the genome to “learn from experience”, regulating gene 
expression in response to dietary and other exposures and 
leading to altered cellular phenotypes associated, for example, 
with chronic disease or ageing (7).
All of these “-omics” sciences have been used to study in 
detail the molecular responses to food substances or the early 
stages of disease in common diet-related conditions (8,9). Nu-
trigenomics will promote an increased understanding of how 
nutrition influences metabolic, caloric and vascular homeosis, 
how this regulation is disturbed in the early phases of diet-
related disease, and the extent to which individual sensitizing 
genotypes contribute to such diseases (10).
Who will be susceptible to disease and who will be 
responsive to dietary modification?
It is well known that there are differences in nutrient require-
ments which for several nutrients follow a normal distribution, 
with some individuals having very high requirements while 
others need much lower levels than average. At the heart of 
individual variation is the 0.1% of variation between the DNA 
sequences of any two individuals. Much of this variation is 
accounted for by single nucleotide polymorphisms (SNP), 
which are largely responsible for differences in complex 
characteristics such as the way in which we respond to our 
environment. These differences are likely to apply throughout 
life, from the early uterine environment right through to dif-
ferent ageing responses later in life. All of these technologies 
have so far been applied to cells in culture and to certain 
model organisms. The challenge will come in applying them 
to people, where problems both of study design and ethics will 
be encountered. In addition, with human beings, our means 
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of establishing accurate dietary exposures are imperfect and 
this is compounded by the need for observations over long 
time periods, by problems of access to the target tissues and 
their heterogeneity. 
NUTRIGENOMICS' FIRST STEPS
Until recently, nutrition research concentrated on nutrient 
deficiencies and health impairment. The advent of genomics 
has created unprecedented opportunities for increasing our 
understanding of how nutrients modulate gene and protein 
expression and ultimately influence cellular and organismal
metabolism. Eventually, nutrigenomics will lead to evidence-
based dietary strategies for restoring health and fitness and for 
predicting and preventing lifestyle-related diseases (Figure). 
Nutrigenomics seeks to provide a genetic understanding 
for how common dietary chemicals (i.e., nutrition) affects the 
balance between health and disease by altering the expression 
and/or structure of an individual’s genetic makeup (11). The 
conceptual basis for this new branch of genomic research can 
best be summarized with the following five tenets (12): (i) 
common dietary chemicals act on the human genome, either 
directly or indirectly, to alter gene expression or structure, (ii) 
under certain circumstances and in some individuals, diet can 
be a serious risk factor for a number of diseases, (iii) some diet-
regulated genes (and their normal, common variants) are likely 
to play a role in the onset, incidence, progression, and/or sever-
ity of chronic diseases, (iv) the degree to which diet influences
the balance between healthy and disease states may depend on 
an individual’s genetic makeup, and (v) dietary intervention 
based on knowledge of nutritional requirement, nutritional 
status, and genotype, that is, “individualized nutrition”, can 
be used to prevent, mitigate or cure chronic disease.
Nutrigenomics refers to the prospective analysis of differ-
ences among nutrients with regard to the regulation of gene 
expression. In this context, nutrigenomics is a discovery sci-
ence driven by the paradigms of molecular biology, enabled 
by microarray technology, and integrated on an informatics 
platform. In contrast, nutrigenetics refers to the retrospective 
analysis of genetic variations among individuals with regard 
to their clinical response to specific nutrients. In this context, 
nutrigenetics is an applied science driven by the paradigms of 
nutritional pharmacology in the context of genetic polymor-
Figure 1. “The Future of Nutritional Science”. From the American Diatetic Association, 2003.
120
Biomed Rev 17, 2006
Dimitrov, Pancheva, Tonchev, Stoeva, Kostov, Georgieva, Ghenev, and Chaldakov
phisms and clinical experience. Although the directionality of 
these distinctions is a useful interim construct, the distinctions 
are likely to erode and the concepts coalesce as the databases 
of the human genome and nutriome merge into a unifying 
paradigm of molecular nutrition (13).
NEW BIOMARKERS FOR DISEASES
The finding that several dietary compounds regulate gene
expression has provided tools to help unravel molecular 
mechanisms behind lifestyle-related diseases. A major focus 
of nutrition research is on the prevention of chronic diseases 
including cardiometabolic and other obesity-linked diseases 
such as nonalcoholic steatohepatitis, polycystic ovary syn-
drome, obstructive sleep apnea syndrome, cancers (reviewed 
in 14-20) and also Alzheimer’s disease (21,22). These disorders 
are partly mediated by chronic exposure to certain food com-
ponents and therefore a critical part of the prevention strategy 
concerns changing food content and food habits (23). 
Discovering natural dietary ligands that regulate important 
metabolic pathways have recently been identified for several
new members of the nuclear receptor superfamily, including 
peroxisome proliferator-activated receptors (PPARs), liver 
X receptors, farnesoid X receptor, constitutive androstane 
receptor, and pregnane X receptor (24). All of these receptors 
are relatively promiscuous, recognizing both endogenous 
and exogenous ligands that often share little or no structural 
similarity. Therefore these receptors are potential mediators of 
nutrients and other natural products that have beneficial effects.
Several nuclear receptors bind substances in the diet or me-
tabolites of dietary substances. This makes nuclear receptors 
a fascinating link between nutrition, genomics, endocrinology 
and molecular biology. For instance, n-3 polyunsaturated fatty 
acids, including linoleic acid, linolenic acid, and the fish oils
docosahexaenoic acid and eicosapentaenoic acid, have all been 
shown to bind and activate PPARγ and PPARδ, though their 
affinity is higher for PPARα. Saturated and monounsaturated 
fatty acids, including palmitic, oleic, and arachidonic acids, 
also bind for PPARα with greater affinity than either activate
PPARγ and PPARδ (25). Further, the emerging studies on 
nutrient-induced gene expression for other obesity-related 
molecules such as adipokines (15-20) frame a novel target of 
nutritional genomics, namely adiponutrigenomics.
ADIPONUTRIGENOMICS OF LIFESPAN: YES, SIR!
Recent data may join adipobiology (15-20) and nutritional 
genomics, including xenohormesis (26,27), in the processes 
of ageing and lifespan (28-32). Encoraging results obtained 
until now include (26-30): (i) yeast, worms, flies, rodents or
humans kept on caloric restriction diet enjoy healthy longev-
ity (26-30), (ii) treatment with resveratrol, a xenohormetic 
molecule of polyphenol nature, extends lifespan of treated 
animals via stimulation of the actvity of nicotinamide adenine 
dinucleotide (NAD)+ deacetylases, e.g. adipose-specific, inner
mitochondrial membrane protein, sirtuin 3 (SIRT3, named 
after the gene Sir, silent information regulator) (31,32 for 
Alzheimer’s disease treatment), (iii) caloric restriction-induced 
increase in lifespan is accompanied by elevated brain levels 
of brain-derived neurotrophic factor (BDNF) (33; 34-36 for 
both BDNF and nerve growth factor, NGF), (v) n-3 polyun-
saturated fatty acids increase circulating levels of adiponectin 
(37), an “anti-kine” (38), that is, adipokine with antiobesity, 
anti-inflammatory, anti-diabetic and anti-atherogenic effects
(reviewed in 15,18), and, noteworthy, (v) resveratrol mim-
ics caloric restriction’s effects, thus promising a (charming) 
chance for Homo besus to enjoy both weight loss and pleasure 
of eating (and drinking).
In perspective, various nutraceuticals such as Pycnogenol 
(39) as well as functional foods may be pursued for their pos-
sible impact on the biology of NGF, BDNF, adiponectin and 
other metabotrophic factors including sirtuins (26-32,34-36); 
such an (adipo)nutrigenomic approach may also be applied to 
an age-related phenomenon recently dubbed inflammageing
(40,41).
CONCLSUION 
Food components may have fundamental influences on health
and disease that can further be explained by studying nutri-
ent-induced gene, protein and metabolite expressions. This 
may help to better understand nutrition’s impact on energy, 
metabolic and vascular homeostasis and thus developing bet-
ter strategies for the prediction, prevention and treatment of, 
at least, lifestyle-related diseases. In the coming years, we 
may indeed identify the mechanisms driving the connection 
between diet and the outward manifestation of genes, the 
“nutritional” phenotype.
Dietary advice is traditionally based on observations at the 
level of large populations. However, advice that is good for 
the majority of people can be bad for a minority with different 
genetic background. There are estimates that dietary guidelines 
designed for entire populations give recommendations that 
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might only work for two people out of three. Hence, potential 
benefits of nutrigenomics research may include an improved
individual health, greater consumer choice and control, greater 
disease prevention and related health care system savings. 
On top of this, nutrigenomics promises to enable people to 
reduce risks of developing diet-related diseases, and may be 
able to treat existing conditions. It is likely that adjustments 
to diets over a long time will strongly reduce the risks of a 
large number of diseases. In effect, genetic passport may help 
launching once’s individualized “diaeteticon” (42). It is not 
only CR (caloric restriction) but, more importantly, escaping 
from any CR (creativity restriction) that may indeed help 
achieving that goal.
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